Rett syndrome

SHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Thursday, March 14, 2024
Patient, Certification, Block & Leviton, Rett syndrome, Clinical trial, Cryptocurrency

BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.

Key Points: 
  • BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Anavex Class Action Lawsuit

Retrieved on: 
Wednesday, March 13, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Anavex Life Sciences Corporation Stock and Sets a Lead Plaintiff Deadline of May 13, 2024

Retrieved on: 
Wednesday, March 13, 2024
Telephone, District court, Patient, News, LLP, Rett syndrome, Clinical trial, MCI, Radar, Court, Person, Cryptocurrency

You are hereby notified that the class action lawsuit Jonathan Blum v. Anavex Life Sciences Corporation, et al.

Key Points: 
  • You are hereby notified that the class action lawsuit Jonathan Blum v. Anavex Life Sciences Corporation, et al.
  • 1:24-cv-01910) has been commenced in the United States District Court for the Southern District of New York.
  • If you suffered a loss in AVXL stock, you have until May 13, 2024 to request that the Court appoint you as lead plaintiff.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.

ProQR Announces Year End 2023 Operating and Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Trident, Eli Lilly, Exercise, ProQR, Patient, IP, Therapy, Lilly, RNA editing, Cholestasis, Rett syndrome, Research, Cardiovascular disease, Partnership, Pseudouridine, NTCP, RNA, Functional, Uridine, MECP2, Oligonucleotide, ACTB, LPL, Annual report, Conference, Patent, Biomarker, Mouse, RSRT, Eli Lilly and Company, Liver, ANGPTL3

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
  • At December 31, 2023, ProQR held cash and cash equivalents of €118.9 million, compared to €94.8 million at December 31, 2022.
  • The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
  • For further financial information for the period ended December 31, 2023, please refer to our 2023 Annual Report on Form 20-F and our Statutory Annual Report which will be available on our website, www.

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Retrieved on: 
Tuesday, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, AbbVie, Prader–Willi syndrome, Scripps Research, IGM, Horizon, Delusion, Executive, Harvey Mudd College, Patient, Acquisition, Rett syndrome, Doctor of Philosophy, Myenteric plexus, Chemistry, Research and development, Hallucination, Rare disease, Amgen, ACAD, FDA, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
  • Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
  • “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
  • She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation

Retrieved on: 
Sunday, March 31, 2024
Class Action Lawsuit, Professional Services, Legal, Rett, Excellence, Central nervous system, Patient, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, March 21, 2024
Class Action Lawsuit, Professional Services, Legal, Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.

Key Points: 
  • Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Anavex Life Sciences Corporation Stockholder Alert: Robbins LLP Reminds Investors of AVXL Class Action

Retrieved on: 
Monday, March 18, 2024
Class Action Lawsuit, Professional Services, Legal, Rett, Excellence, Central nervous system, Patient, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Tuesday, March 19, 2024
Class Action Lawsuit, Professional Services, Legal, Central nervous system, Patient, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Toxicity, Administration, Information technology, MECP2, Inc., Patient, Cash, Batten disease, Cohort, Female, Insurance, Rett syndrome, Research and development, Investment, Clinical trial, Net, Data, DSM-IV codes, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.
  • We believe this expanded dataset will support future regulatory discussions to align on the design of a potential registrational study,” said Rachel McMinn, Ph.D., Chief Executive Officer and Founder of Neurogene.
  • “NGN-401 has the potential to be a best-in-class treatment option with a targeted route of administration to deliver full-length, functional copies of the MECP2 gene.
  • Net income for the three months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.